西洛他唑对2型糖尿病患者尿白蛋白排泄率的影响(英文)

Effect of Cilostazol on urinary albumin excretion rate in type 2 diabetic patients

目的探讨西洛他唑治疗2型糖尿病早期肾病的临床疗效。方法将60例血压正常伴微量白蛋白尿的2型糖尿病患者,随机分为两组:治疗组30例,予口服西洛他唑片(50mg,2次/d);对照组30例,予口服安慰剂维生素B1(10mg,2次/d),两组均治疗3个月。观察患者治疗前后尿白蛋白排泄率(UAER)的变化。结果治疗组较治前,UAER明显下降(P<0.01),下降幅度达51.6%,肝肾功能均正常,约3%病人仅有轻微头痛反应。对照组治疗前后UAER无明显变化(均P>0.05)。结论西洛他唑能显著降低糖尿病患者尿白蛋白的排泄,对糖尿病早期肾病具有治疗作用,且安全性好。

[Objective] To evaluate the efficacy of Cilostazol in treating incipient diabetic nephropathy in type 2 diabetic patients. [Methods] Sixty cases of normotensive type 2 diabetes with microalbuminuria were randomized into two groups, 30 cases in each. The Cilostazol-treated group was orally given Cilostazol （50 mg, bid） for 3 months. Whereas, the control group received vitamin B1 （10 mg, bid） also for 3 months. Before and after the study, urinary albumin excretion rate COAER） was investigated. [Results] in Cilostazol-treated group UAER was markedly decreased （P 〈0.01） by 51.6%. Renal and liver function tests were kept normal. Only 3% of the patients developed mild headache during Cilostazol treatment. By contrast, UAER did not show any significant change in control group （P 〉0.05）. [Conclusion] Cilostazol decreases urine albumin excretion efficiently in the diabetic patients with incipient diabetic nephropathy. Cilostazol is safe and well tolerated. d